{"id":49631,"date":"2022-10-14T12:01:54","date_gmt":"2022-10-14T10:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/"},"modified":"2022-10-14T12:01:54","modified_gmt":"2022-10-14T10:01:54","slug":"bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/","title":{"rendered":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab)"},"content":{"rendered":"<div>\n<p>GUANGZHOU, China&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/Asthma?src=hash\" target=\"_blank\" rel=\"noopener\">#Asthma<\/a>&#8211;Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala<sup>\u00ae<\/sup> (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel group, single-dose study that is expected to enroll approximately 207 healthy volunteers.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/4\/New_Bio-Thera_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg\"><\/a><\/p>\n<p>\nMepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody that is administered subcutaneously with a syringe or autoinjector. Mepolizumab is currently indicated for the following conditions: 1) as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype, 2) as an add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal, 3) the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, 4) the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome for \u22656 months without an identifiable non-hematologic secondary cause.\n<\/p>\n<p>\nAfter the conclusion of the Phase 1 study Bio-Thera plans to run a global Phase 3 study and request approval for all available indications at the time of filing the BLA\/MAA with NMPA, FDA, EMA and other regulatory bodies around the world.\n<\/p>\n<p>\nBio-Thera Solutions is developing several additional biosimilar products for the global market including biosimilar versions of Avastin<sup>\u00ae<\/sup>, Actemra<sup>\u00ae<\/sup>, Cosentyx<sup>\u00ae<\/sup>, Simponi<sup>\u00ae<\/sup> and Stelara<sup>\u00ae<\/sup>. QLETLI<sup>\u00ae<\/sup>, a biosimilar to Humira<sup>\u00ae<\/sup>, and Pobevcy<sup>\u00ae<\/sup>, a biosimilar to Avastin<sup>\u00ae<\/sup>, are approved by the NMPA and being commercialized in China.\n<\/p>\n<p>\n<b>About Bio-Thera Solutions<\/b>\n<\/p>\n<p>\nBio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. A leader in next generation antibody discovery and engineering, the company has advanced six candidates into late-stage clinical trials and has two approved products, QLETLI<sup>\u00ae<\/sup> and POBEVCY<sup>\u00ae<\/sup> in China. In addition, the company has multiple promising candidates in early clinical trials and IND-enabling studies, focusing on immuno-oncology, ADC targeted therapies, autoimmune diseases, and other severe and emerging unmet medical needs. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bio-thera.com%2Fen%2F&amp;esheet=52944796&amp;newsitemid=20221014005147&amp;lan=en-US&amp;anchor=www.bio-thera.com%2Fen%2F&amp;index=1&amp;md5=e4391c059f3cbe61d67cb9af104a316c\" rel=\"nofollow noopener\" shape=\"rect\">www.bio-thera.com\/en\/<\/a> or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).\n<\/p>\n<p>\n<b>Cautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n<p>\nThis news release contains certain forward-looking statements relating to BAT2606 or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing \u201ccould,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201cpromising,\u201d \u201cpotentially,\u201d or similar expressions. They reflect the company\u2019s current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies, for example, the development processes could be lengthy and high <i>in vitro<\/i> affinity may not translate to desired results <i>in vivo <\/i>or successful clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company\u2019s financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company\u2019s views or otherwise.\n<\/p>\n<p>\n1 Nucala<sup>\u00ae<\/sup> is a registered trademark of GSK plc<br \/>\n<br \/>2 Avastin<sup>\u00ae<\/sup> is a registered trademark of Genentech, Inc<br \/>\n<br \/>3 Actemra<sup>\u00ae<\/sup> is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corporation<br \/>\n<br \/>4 Cosentyx<sup>\u00ae<\/sup> is a registered trademark of Novartis AG<br \/>\n<br \/>5 Simponi<sup>\u00ae<\/sup> is a registered trademark of Johnson &amp; Johnson Corporation<br \/>\n<br \/>6 Stelara<sup>\u00ae<\/sup> is a registered trademark of Johnson &amp; Johnson Corporation<br \/>\n<br \/>7 QLETLI<sup>\u00ae<\/sup> is a registered trademark of Bio-Thera Solutions, Ltd<br \/>\n<br \/>8 Humira<sup>\u00ae<\/sup> is a registered trademark of AbbVie Biotechnology Ltd<br \/>\n<br \/>9 Pobevcy<sup>\u00ae<\/sup> is a registered trademark of Bio-Thera Solutions, Ltd\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nBio-Thera Solutions, Ltd.:<br \/>\n<br \/>Bert E. Thomas IV +1.410.627.1734<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;b&#101;&#x74;&#x68;o&#109;&#x61;&#x73;&#64;&#98;&#x69;&#x6f;-&#116;&#x68;&#x65;r&#97;&#x2e;c&#111;&#109;?subject=BAT1806%20Phase%20I%20Press%20Release\" rel=\"nofollow noopener\" shape=\"rect\">&#x62;&#101;&#116;h&#x6f;&#x6d;&#97;s&#x40;&#x62;&#105;o-&#x74;&#104;&#101;r&#x61;&#x2e;&#99;o&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>GUANGZHOU, China&#8211;(BUSINESS WIRE)&#8211;#Asthma&#8211;Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala\u00ae (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49631","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GUANGZHOU, China&#8211;(BUSINESS WIRE)&#8211;#Asthma&#8211;Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala\u00ae (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-14T10:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab)\",\"datePublished\":\"2022-10-14T10:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/\"},\"wordCount\":752,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005147\\\/en\\\/760455\\\/21\\\/New_Bio-Thera_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/\",\"name\":\"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005147\\\/en\\\/760455\\\/21\\\/New_Bio-Thera_Logo.jpg\",\"datePublished\":\"2022-10-14T10:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005147\\\/en\\\/760455\\\/21\\\/New_Bio-Thera_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005147\\\/en\\\/760455\\\/21\\\/New_Bio-Thera_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab) - Pharma Trend","og_description":"GUANGZHOU, China&#8211;(BUSINESS WIRE)&#8211;#Asthma&#8211;Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala\u00ae (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-14T10:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab)","datePublished":"2022-10-14T10:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/"},"wordCount":752,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/","url":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/","name":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg","datePublished":"2022-10-14T10:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221014005147\/en\/760455\/21\/New_Bio-Thera_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat2606-a-proposed-biosimilar-of-nucala-mepolizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49631"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49631\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}